ahlam1399
07-27-2016, 02:27 AM
Recro Pharma?s intrave**us painkiller succeeds in trial, shares soar
(Reuters) – Recro Pharma Inc said an intrave**us version of its lead painkiller was successful in the first of two pivotal late-stage trials, sending the company’s shares surging 50 percent in trading after the bell.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=wYQRxCuNKbQ:8syyCk-QdeA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=wYQRxCuNKbQ:8syyCk-QdeA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/wYQRxCuNKbQ
(Reuters) – Recro Pharma Inc said an intrave**us version of its lead painkiller was successful in the first of two pivotal late-stage trials, sending the company’s shares surging 50 percent in trading after the bell.http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=wYQRxCuNKbQ:8syyCk-QdeA:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=wYQRxCuNKbQ:8syyCk-QdeA:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=wYQRxCuNKbQ:8syyCk-QdeA:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/wYQRxCuNKbQ